This was the stock's fourth consecutive day of gains.

Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy ...

Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by ...

Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and ...

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

Bio-Techne has a market capitalization of $12.25 billion. The Zacks Consensus Estimate for the company’s fiscal 2025 earnings indicates a 5.1% year-over-year increase on a 5.6% revenue improvement.

This was the stock's third consecutive day of gains.

Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse ...

Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium While mutations in the ESR1 gene are exceedingly rare in cancer patients prior to treatment, the use of ...